Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q2 2018 · 10-Q
Revenue$111.81K$111.81K+9.6% vs Q2 2017 Net Income-$3.75M-$3.75MN/M vs Q2 2017 EPS Diluted-$5.27-$5.27N/M vs Q2 2017 Operating Income-$4,439,596N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,250,607N/M Margins · derivedOperating margin-3970.6%+1801.6 pt vs Q2 2017
Net margin-3351.1%+4536.1 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 3, 2018 · 34 d after period end